STRADA

Across TCGA pan-cancer cohorts, STRADA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STRADA data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STRADA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STRADA expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where STRADA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.388	0.907	.010	15	view →
LSCC	OS	Median	All	0.886	0.743	.021	8	view →
CCRCC	DFS	Quartile	III,IV	0.811	0.476	.009	4	view →
LUAD	DFS	Quartile	II,III,IV	0.792	0.140	.031	2	view →
HNSC	DFS	Tertile	All	0.794	0.591	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STRADA–PDAC (DFS)

Open the PDAC breakdown →